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Abstract : First-generation drug-eluting stents （DESs） have reduced angiographic 
and clinical restenosis rates compared to bare-metal stents （BMSs）.  Zotaroli-
mus-eluting stents （ZESs） are second-generation drug-eluting stents : however, 
the clinical efcacy of ZES implantation is unclear because late loss associated 
with ZESs is reportedly higher than that observed for other DESs.  The 
aim of this study was to evaluate the clinical efcacy of ZESs compared to 
paclitaxel-eluting stents （PESs）.  We retrospectively evaluated the angiographic 
and clinical outcomes of 431 lesions in 342 patients treated with PESs and 153 
lesions in 121 patients treated with ZESs in our hospital between May 2007 
and December 2010.  Follow-up angiographic examinations were performed 
eight months post-treatment and clinical outcomes were assessed one year after 
the procedure.  Quantitative coronary angiographic analyses showed that late 
loss was signicantly higher for ZESs than PESs （0.82 ± 0.73 mm vs 0.47 ±
0.68 mm ; P＝0.003）.  However, there was no signicant difference in target 
lesion revascularization （TLR） between the two groups （ZES : 15 lesions, 
9.8％ vs PES : 25 lesions, 5.8％ ; P＝0.092）.  When comparing stents according 
to the American College of Cardiology / American Heart Association （ACC /
AHA） lesion type, the TLR rate in the ZES group was signicantly lower 
than in the PES group （0％ vs 7.0％ ; P＝ 0.038） for Type A / B1 lesions, but 
the TLR rate for type B2 / C lesions in the ZES group was signicantly higher 
than in the PES group （15.8％ vs 5.3％ ; P＝0.009）.  Multivariate logistic 
regression analysis showed that dialysis （OR : 35.54 ; 95％ CI : 3.15-400.67 ; 
P＝0.039） and pre-minimal lumen diameter （OR : 0.036 ; 95％ CI : 0.002-
0.541 ; P＝0.016） were independent predictors of TLR in ZES-treated lesions.  
However, no factors predicted TLR in PES-treated lesions.  Our study dem-
onstrated excellent outcomes with ZESs for simple lesions, but it is necessary 
to carefully implant ZESs in complex lesions, such as ACC / AHA type B2 / C 
lesions..
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Introduction
　Previous studies have reported that patients treated with first-generation drug-eluting 
stents （DESs） had improved angiographic and clinical outcomes compared to those treated 
with bare-metal stents （BMSs）1, 2）.  Zotarolimus-eluting stents （ZESs ; Endeavor, Medtronic 
CardioVascular, Santa Rosa, CA, USA） are second-generation drug-eluting stents that deliver 
the potent anti-proliferative agent zotarolimus through a biocompatible phosphorylcholine 
polymer, that has a shorter drug-elution time （within two weeks）, on a cobalt chromium-
based thin-strut （0.0036”） stent 3, 4）.  ZESs have been available in Japan since May 2009, and 
treatment with ZESs is associated with signicant reductions in angiographic restenosis and 
target lesion revascularization （TLR） compared to treatment with BMSs5, 6）.  However, the 
clinical efcacy after implantation of ZESs remains unclear because the late loss associated 
with ZESs is reportedly higher than that associated with other DESs7）.  Limited information 
is available about the angiographic and clinical outcomes of rst-generation DESs and ZESs, 
and few studies have focused on the impact of differential lesion complexity on the efcacy 
of these treatments3, 8）.  The aim of this study was to evaluate and compare the clinical ef-
cacies of the second generation DES, ZES, and the paclitaxel-eluting stent （PES ; TAXUS, 
Boston Scientic Corporation, Natick, MA, USA）, a rst-generation DES.  Furthermore, we 
performed a stratied analysis according to lesion complexity and compared the efcacies of 
ZESs and PESs in complex lesions, which were dened as type B2 / C lesions, and in simple 
lesions, which were dened as type A / B1 lesions.
Methods
Study population
　We retrospectively evaluated the angiographic and clinical outcomes of 431 lesions in 342 
patients treated with PESs and 153 lesions in 121 patients treated with ZESs in daily prac-
tice between May 2007 and Dec 2010 at our hospital.  Follow-up angiographic examinations 
were performed eight months post-treatment and clinical outcomes were assessed one year 
after the procedure.
Angioplasty procedures
　All procedures were performed with a 7- or 8-French-gauge guiding catheter and a 
femoral approach.  Stents were deployed with or without predilatation according to standard 
techniques.  In all cases, the stent was placed so that its entire length covered the lesion, 
and dilation pressure was applied to the stent until the lesion was sufciently dilated under 
transillumination.  Intravascular ultrasound （IVUS） was used in all cases during predilatation 
to determine stent diameter, and following stent deployment and post-dilatation to check 
stent apposition.  After stent implantation, aspirin （at least 100 mg / day） was prescribed 
for an indenite duration, and clopidogrel （75 mg / day） or ticlopidine （200 mg / day） was 
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administered for at least 12 months.
Denitions
　Anginal symptoms were dened according to the Canadian Cardiovascular Society clas-
sication.  Major adverse cardiac events （MACE） were dened as death from any cause, 
myocardial infarction （MI）, or TLR.  TLR was defined as any repeat revascularization 
procedure （percutaneous or surgical） of the original target lesion site.  Target vessel revas-
cularization was dened as clinically driven percutaneous revascularization or bypass of the 
target lesion or any segment of the epicardial coronary artery containing the target lesion. 
Acute coronary syndrome （ACS） was dened as acute myocardial infarction or unstable 
angina pectoris.  A calcied lesion was dened as an identiable radiopaque image in the 
case of still images obtained before injecting contrast agent or an identiable dark image on 
moving images.  Lesions longer than 20 mm were dened as long lesions.  Target restenosis 
was dened as stenosis of 50％ or more based on follow-up remote-phase coronary angiog-
raphy results.  In addition, we dened type A / B1 lesions as “simple” lesions and type B2 /
C lesions as “complex” lesions.
　Quantitative coronary angiography （QCA） was performed with the QCA-CMS cardiovas-
cular analysis system manufactured by Medis.  Lesion length, minimum vascular diameter, 
and control vascular diameter were measured from the dilated phase frames, and all 
measurements were taken from an angle showing minimal lesion contraction.  The same 
angles were used in pre-treatment, post-treatment, and follow-up remote-phase coronary angi-
ography.  The rate of stenosis, acquired inner diameter in the acute phase, and loss of inner 
diameter in the remote phase were then calculated.
Statistical analysis
　Quantitative data are presented as the mean ± SD, and categorical data are presented as 
percentages.  Statistical analysis was performed using the chi-square test or Fisher’s exact 
test （two-tailed） for categorical variables.  Student’s t-tests were used for the comparison of 
continuous variables, and P values of 0.05 or less were considered signicant.  Univariate 
and multivariate analyses of continuous ratios, including 95％ condence intervals （CI）, were 
calculated using the Cox proportional hazards model.  Factors with P values less than 0.05 
in the univariate analysis were entered into the multivariate model.  Statistical analysis was 
performed using commercially available software.
Results
　Baseline patient characteristics were similar among all ZES and PES patients except for 
the higher percentages of dialysis and smoking in the PES group （P＝ 0.028 and P＝ 0.002, 
respectively） and the higher percentage of ACS in the ZES group （P＜ 0.0001 ; Table 1）.
　Lesion characteristics and quantitative angiographic analysis data are listed in Table 2. 
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There were no signicant differences in target vessel location, chronic total occlusion lesions, 
bifurcation lesions, long lesions, or small vessels between the two groups.  The number of cal-
cied lesions in the PES group was signicantly higher than in the ZES group （P＝ 0.0006）. 
With respect to lesion complexity determined according to the modied American College of 
Cardiology / American Heart Association （ACC / AHA） classication, 62.1％ of ZES lesions 
and 70.3％ of PES lesions were characterized as complex lesions.  Although the percentage 
of complex lesions in the PES group was higher than that in the ZES group, the difference 
was not significant （P＝0.061）.  However, the percentage of type A lesions in the ZES 
group was signicantly higher than in the PES group （P＝0.002）, and the percentage of type 
C lesions in the PES group was signicantly higher than in the ZES group （P＝ 0.001）.
　The eight-month angiographic follow-up rate was 51％.  At eight months, there were 
signicant differences in the minimal lumen diameter （MLD）, percent diameter stenosis （％
DS）, and late loss between the two groups.  Late loss was signicantly higher in the ZES 
group than in the PES group （0.82 ± 0.73 mm vs 0.47 ± 0.68 mm ; P＝ 0.003）, although the 
difference in the restenosis rate between the two groups was not signicant （P＝ 0.191）.  At 
the one-year clinical follow-up, MI occurred in three patients in the PES group but not in 
the ZES group, and there were three deaths in the ZES group and six deaths in the PES 
group, but the differences were not signicant （P＝ 0.328 and P＝ 0.512, respectively ; Table 
3）.  Despite the signicant difference in late loss, the difference in the TLR rate was not 
signicant between both stent types （ZES : 15 lesions, 9.8％ vs PES : 25 lesions, 5.8％ ; P＝
0.092）.  In addition, the percentage of total MACE was not signicantly different between 
the two groups （ZES : 11.8％ vs PES : 7.2％ ; P＝ 0.080）.
Table 1.  Baseline characteristics of all patients
ZES PES P value
Patients, n 121 342
Age, years 66.35 ± 12.71 67.35 ± 10.26 0.386
Male gender, n （％） 95（78.5） 273（79.8） 0.759
Risk factor
　Hypertension, n （％） 90（74.4） 223（65.2） 0.064
　Diabetes mellitus, n （％） 63（52.1） 182（53.2） 0.828
　Dyslipidemia, n （％） 81（66.9） 205（59.9） 0.173
　Current or past smoking, n （％） 75（62.0） 157（45.9） 0.002
　Dialysis, n （％） 5（4.1） 37（10.8） 0.028
　Family history, n （％） 20（16.5） 65（19.0） 0.545
　Left ventricular ejection fraction, ％ 52.57 ± 10.93 51.61 ± 13.08 0.531
Clinical presentation
　Stable angina or silent ischemia, n （％） 53（43.8） 226（66.1） -
　Unstable angina or acute myocardial infraction, n （％） 68（56.2） 116（33.9） P＜ 0.0001
ZES, zotarolimus-eluting stents ; PES, paclitaxel-eluting stents
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Subgroup analysis stratied by lesion complexity
　When comparing the two groups based on lesion complexity, the baseline patient character-
istics stratied by complexity were well balanced between the ZES and PES groups for both 
simple and complex lesions.  However, there was a higher percentage of dialysis patients in 
the PES group with simple lesions （P＝ 0.012） and a higher percentage of smoking patients 
Table 2.  Lesion characteristics and quantitative coronary analysis in all patients
ZES PES P value
Lesion, n 153 431
Lesion characteristics
　Target vessel
　　Left main trunk, n （％） 16（10.5） 48（11.1） 0.817
　　Left anterior descending, n （％） 65（42.5） 181（42.0） 0.916
　　Left circumex, n （％） 37（24.2） 97（22.5） 0.672
　　Right coronary, n （％） 50（35.0） 152（35.3） 0.563
　Bifurcation, n （％） 64（41.8） 204（47.3） 0.241
　Long lesion, n （％） 74（48.4） 209（48.5） 0.979
　Calcied lesion, n （％） 16（10.5） 101（23.4） 0.0006
　Small vessel lesion, n （％） 61（39.9） 140（32.5） 0.099
　CTO, n （％） 12（7.8） 47（10.7） 0.28
　AHA lesion type
　　A, n （％）  24（15.7） 31（7.2） 0.002
　　B1, n （％） 34（22.2） 97（22.5） 0.942
　　B2, n（％） 61（39.9） 144（33.4） 0.151
　　C, n （％） 34（22.2） 159（36.9） 0.001
　　type B2 / C, n （％） 95（62.1） 303（70.3） 0.061
QCA
　Pre-PCI
　　MLD, mm 0.58 ± 0.50 0.51 ± 0.43 0.152
　　RD, mm 2.97 ± 1.24 2.67 ± 0.71 0.863
　　％DS, ％ 85.1 ± 13.8 80.3 ± 17.6 0.408
　Post-PCI
　　MLD, mm 2.65 ± 0.68 2.62 ± 0.54 0.708
　　RD, mm 2.99 ± 0.57 3.05 ± 0.59 0.402
　　％DS, ％ 12.0 ± 6.6 14.6 ± 10.7 0.011
　Follow-up
　　MLD, mm 1.89 ± 0.84 2.11 ± 0.73 0.041
　　RD, mm 2.78 ± 0.50 4.31 ± 0.50 0.467
　　％DS, ％ 32.4 ± 26.2 25.6 ± 22.6 0.037
　Acute gain, mm 2.08 ± 0.59 2.08 ± 0.59 0.903
　Late loss, mm 0.82 ± 0.73 0.47 ± 0.68 0.003
CTO, chronic total occlusion ; QCA, quantitative coronary analysis
PCI, percutaneous coronary intervention ; MLD, minimal lumen diameter ;
RD, reference diameter ; ％DS, ％ diameter stenosis
ZES, zotarolimus-eluting stents ; PES, paclitaxel-eluting stents
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in the ZES group with both simple and complex lesions （P＝ 0.032 and P＝ 0.036, respec-
tively ; Table 4）.  There were also signicant differences in diagnoses among patients with 
both simple and complex lesions （P＝ 0.005 and P＝ 0.001, respectively）.
　Lesion characteristics and quantitative angiographic analysis data stratied by complexity 
are listed in Table 5.  Lesion locations between the two groups were well matched except 
for the higher percentage of left anterior descending locations of simple lesions in the ZES 
group （P＝ 0.002） and right coronary artery locations of simple lesions in the PES group 
Table 3.  Restenosis and clinical outcomes in all patients
Variable ZES （n＝153） PES （n＝431） P value
Restenosis, n （％） 20（13.1） 76（17.6） 0.191
MACE, n （％） 18（11.8） 31（7.2） 0.080
　Target lesion revascularization, n （％） 15（9.8） 25（5.8） 0.092
　Death, n （％） 3（2.0） 6（1.4） 0.512
　Myocardial infarction, （％） 0（0） 3（0.7） 0.328
　Target vessel revascularization, n （％） 19（12.4） 38（8.8） 0.197
　CABG, n （％） 0（0） 3（0.7） 0.328
MACE, major adverse cardiac event : all-cause death, myocardial infarction, target lesion revascularization
CABG, coronary artery bypass graft ; ZES, zotarolimus-eluting stents ; PES, paclitaxel-eluting stents
Table 4.  Patient characteristics, stratied by complexity
Simple （A / B1） lesion （n＝151） Complex （B2 / C） lesion （n＝312）
Variable ZES PES P value ZES PES P value
Patients, n 44 107 77 235
Age, years 67.96 ± 11.86 67.57 ± 9.75 0.837 65.43 ± 13.15 67.25 ± 10.51 0.217
Male, n （％） 34（77.3） 87（81.3） 0.572 61（79.2） 186（79.1） 0.989
Risk factor
　Hypertension, n （％） 33（75.0） 73（68.2） 0.408 57（74.0） 150（63.8） 0.100
　Diabetes mellitus, n （％） 25（56.8） 58（54.2） 0.769 38（49.4） 124（52.8） 0.603
　Dyslipidemia, n （％） 34（77.3） 68（63.6） 0.102 47（61.0） 137（58.3） 0.671
　Current or past smoking, n （％） 31（70.5） 55（51.4） 0.032 44（57.1） 102（43.4） 0.036
　Dialysis, n （％） 0（0） 14（13.1） 0.012 5（6.5） 23（9.8） 0.380
　Family history, n （％） 10（22.7） 24（22.4） 0.968 10（13.0） 41（17.4） 0.358
Left ventricular ejection fraction, ％ 53.79 ± 12.06 54.44 ± 11.96 0.801 51.86 ± 10.24 50.22 ± 13.44 0.391
Clinical presentation
　Stable angina or silent ischemia, n （％） 21（47.7） 77（72.0） - 32（41.6） 150（63.8） -
　 Unstable angina or acute myocardial 
infraction, n （％） 23（52.3） 30（28.0） 0.005 45（58.4） 85（36.2） 0.001
ZES, zotarolimus-eluting stents ; PES, paclitaxel-eluting stents
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（P＝ 0.007）.  As to complex lesions, the percentage of left circumex lesions in the PES 
group was higher, but the difference was not signicant （P＝ 0.051）.  The number of calci-
ed simple and complex lesions in the PES group was signicantly higher than in the ZES 
group （P＝ 0.002 and P＝ 0.044, respectively）.
　When comparing QCA data among the patients with simple lesions, no differences were 
found between the ZES and PES groups, including late loss.  Conversely, in patients with 
complex lesions, there were signicant differences in follow-up MLD （ZES : 1.71 ± 0.91 mm 
vs PES : 2.08 ± 0.78 mm ; P＝0.029）, ％DS （ZES : 38.79％± 29.99％ vs PES : 25.71％±
24.28％ ; P＝0.017）, and late loss （ZES : 0.97 ± 0.83 mm vs PES : 0.48 ± 0.72 mm ; P＝0.002）.
Table 5.  Lesion characteristics and quantitative coronary analysis, stratied for complexity
Simple （A / B1） lesion （n＝186） Complex （B2 / C） lesion （n＝312）
ZES PES P value ZES PES P value
Lesion, n 58 128 95 303
Lesion characteristics
　Target vessel
　　Left main trunk, n （％） 2（3.4） 2（1.6） 0.412 14（14.7） 46（15.2） 0.916
　　Left anterior descending, n （％） 31（53.4） 38（29.7） 0.002 34（35.8） 143（47.2） 0.051
　　Left circumex, n （％） 11（19.0） 29（22.7） 0.570 26（27.4） 68（22.4） 0.324
　　Right coronary, n （％） 15（25.9） 60（46.9） 0.007 35（36.8） 92（30.4） 0.237
　Bifurcation, n （％） 11（19.0） 34（26.6） 0.262 53（55.7） 170（56.1） 0.957
　Long lesion, n （％） - - - 55（23.9） 55（23.9） 0.140
　Calcied lesion, n （％） 0（0） 19（14.8） 0.002 16（16.8） 82（27.1） 0.044
　Small vessel lesion, n （％） 19（32.8） 32（25.0） 0.272 42（44.2） 108（35.6） 0.133
　CTO, n （％） - - - 12（12.6） 47（15.5） 0.491
QCA
　Pre-PCI
　　MLD, mm 0.81 ± 0.51 0.70 ± 0.43 0.246 0.44 ± 0.44 0.55 ± 0.43 0.136
　　RD, mm 2.78 ± 0.60 2.64 ± 0.64 0.273 2.62 ± 0.66 2.69 ± 0.77 0.605
　　％DS, ％ 72.1 ± 15.2 75.6 ± 13.4 0.209 82.8 ± 16.7 78.5 ± 19.5 0.154
　Post-PCI
　　MLD, mm 2.77 ± 0.62 2.76 ± 0.41 0.897 2.57 ± 0.45 2.55 ± 0.61 0.856
　　RD, mm 3.09 ± 0.64 3.10 ± 0.48 0.875 2.93 ± 0.51 3.01 ± 0.55 0.405
　　％DS, ％ 10.3 ± 5.7 11.4 ± 7.5 0.392 13.1 ± 7.0 14.3 ± 13.7 0.466
　Follow-up
　　MLD, mm 2.19 ± 0.63 2.28 ± 0.66 0.551 1.71 ± 0.91 2.08 ± 0.78 0.029
　　RD, mm 2.81 ± 0.66 2.89 ± 0.45 0.544 2.75 ± 0.48 2.77 ± 0.67 0.890
　　％DS, ％ 22.1 ± 13.3 21.5 ± 18.5 0.857 38.8 ± 30.0 25.7 ± 24.3 0.017
　Acute gain, mm 1.95 ± 0.59 2.04 ± 0.56 0.443 2.15 ± 0.58 2.04 ± 0.60 0.272
　Late loss, mm 0.59 ± 0.45 0.49 ± 0.57 0.431 0.97 ± 0.83 0.48 ± 0.72 0.002
CTO, chronic total occlusion ; QCA, quantitative coronary analysis
PCI, percutaneous coronary intervention ; MLD, minimal lumen diameter ; RD, reference diameter
％DS, ％ diameter stenosis ;  ZES, zotarolimus-eluting stents ; PES, paclitaxel-eluting stents
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　Restenosis rates and clinical outcomes stratied by complexity are summarized in Table 6. 
Among the patients with simple lesions, the TLR rate in the ZES group was signicantly 
lower than that in the PES group （ZES : 0％ vs PES : 7.0％ ; P＝ 0.038）.  Although there 
was a higher percentage of MACE in the PES group （ZES : 1.7％ vs PES : 9.4％）, the 
difference was not signicant （P＝ 0.058）.  In the complex lesion subgroup, the TLR rate 
in the ZES group was signicantly higher than in the PES group （ZES : 15.8％ vs PES : 
5.3％ ; P＝0.009）.  In addition, the percentage of total MACE in the ZES group with 
complex lesions was significantly higher than in the PES group （ZES : 17.9％ vs PES : 
6.6％ ; P＝ 0.0004）.
Multivariate analysis
　Multivariate logistic regression analysis showed that dialysis ［odds ratio （OR）: 35.54 ; 95％ 
CI : 3.15-400.67 ; P＝ 0.039］ and pre-MLD （OR : 0.036 ; 95％ CI : 0.002-0.541 ; P＝ 0.016） 
were independent predictors of TLR in lesions treated with ZESs.  In contrast, no factors 
predicted TLR in patients with lesions treated with PESs.
Discussion
　Although DESs are now widely used, the clinical efficacy of ZES implantation still 
remains unclear, as it has been reported that the late loss in patients treated with ZESs is 
higher than that observed in patients treated with other DESs7）.  There is limited informa-
tion about the angiographic and clinical outcomes of patients treated with rst-generation 
DESs and ZESs, and to the best of our knowledge, few studies have focused on examining 
these variables based on differential lesion complexity.  We therefore retrospectively com-
pared the angiographic and clinical outcomes of patients treated with the second-generation 
Table 6.  Restenosis and clinical outcomes stratied by complexity
Simple （A / B1） lesion （n＝ 186） Complex （B2 / C） lesion （n＝ 398）
Variable ZES （n＝58）PES （n＝128）P value ZES （n＝95） PES （n＝303）P value
Restenosis, n （％） 2（3.4） 23（18.0） 0.007 19（20） 53（17.5） 0.580
MACE, n （％） 1（1.7） 12（9.4） 0.058 18（17.9） 20（6.6） 0.0004
　 Target lesion revascularization, 
n （％）
0（0） 9（7.0） 0.038 15（15.8） 16（5.3） 0.009
　Death, n （％） 1（1.7） 1（0.8） 0.513 3（3.2） 6（2.0） 0.501
　Myocardial infarction, （％） 0（0） 2（1.6） 0.361 0（0） 2（0.7） 0.427
　 Target vessel revascularization, 
n （％）
1（1.7） 11（8.6） 0.077 18（18.9） 27（8.9） 0.007
　CABG, n （％） 0（0） 0（0） - 0（0） 3（1.0） 0.319
MACE, major adverse cardiac event : all-cause death, myocardial infarction, target lesion revascularization
CABG, coronary artery bypass graft ; ZES, zotarolimus-eluting stents ; PES, paclitaxel-eluting stents
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DES, ZES, and the rst-generation DES, PES, based on lesion complexity.
　In our study, approximately 73.8％ of the study population had high-risk ACC / AHA type 
B2 / C coronary lesions.  With respect to clinical diagnosis and regardless of lesion complex-
ity, the percentage of ACS patients was higher in the ZES group than in the PES group. 
In addition, there were signicant differences between the ZES and PES groups with respect 
to lesion characteristics : the percentage of type A lesions was signicantly higher in the 
ZES group than in the PES group.  However, the percentages of type C lesions and calci-
ed lesions in the PES group were signicantly higher than in the ZES group.  Additionally, 
there were signicant differences between the ZES and PES groups with respect to the per-
centage of dialysis patients.  Several explanations exist for these differences.  Firstly, patients 
in this study were not randomly assigned to a given DES type.  In our hospital, the use of 
ZESs was preferred for ACS cases over other DESs.  Similarly, the use of PESs was pre-
ferred for dialysis cases over other DESs, as PESs are reportedly more effective in dialysis 
cases 9）.  It is possible that there could be a relationship between the higher percentage of 
dialysis and lesion calcication in the PES group.  Secondly, several randomized studies have 
demonstrated the superiority of DESs over BMSs for the treatment of ACS 10）.  However, 
during the era of rst-generation DESs, the use of DESs for ACS cases was debated due 
to the risk of late and very late stent thrombosis （VLST）11-13）.  Therefore, the use of BMSs 
for ACS cases instead of rst-generation DESs, such as sirolimus-eluting stents （SESs） and 
PESs, is preferred in our hospital.  Thirdly, everolimus-eluting stents （EESs ; Abbott Vascular, 
Santa Clara, CA, USA） have been available in Japan since February 2010, and they are 
used more commonly than ZESs in complex cases in our hospital.
　Upon analyzing the angiographic data after ZES implantation, the late loss was found 
to be greater （0.82 ± 0.73 mm） in the current study than previously reported （0.61 ±
0.49 mm）7）.  In addition, the late loss in the ZES group was signicantly greater than that 
in the PES group.  There are three reasons for the greater late loss observed in the ZES 
group compared to the PES group4）.  Firstly, the increased neointimal hyperplasia associated 
with ZESs is due to differences in the pharmacological activity of zotarolimus compared to 
other DESs.  Secondly, the more rapid elution kinetics of zotarolimus from the phosphor-
ylcholine polymer, which results in 95％ elution over approximately 15 days 14）, inuences 
the biological efficacy of ZESs compared to the slower release of other DESs.  Thirdly, 
there are differences in the biological responses to either the stent or the phosphorylcholine 
polymer itself.  Whereas the late loss seen in the ZES group was overall signicantly greater 
than in the PES group in our study, the difference in the TLR rate was not signicant 
（ZES : 9.8％ vs PES : 5.8％ ; P＝ 0.092）.  However, the TLR rate in the ZES group was 
relatively higher than previously reported （4.5％15） and 4.9％16））.
　In the lesion complexity subgroups divided according to ACC / AHA lesion type, ZESs 
resulted in excellent outcomes for A / B1 lesions, which were classied as “simple” lesions. 
However, for B2 / C lesions, which were classified as “complex” lesions, the incidence of 
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TLR was signicantly higher in the ZES group than in the PES group.  The complexity 
of lesions increased the incidence of TLR in the ZES group.  Lotan et al investigated and 
compared real-world outcomes of ZESs based on data from the E-Five Registry.  Patients 
ranged from those requiring standard use ZES treatment for simple lesions to those need-
ing extended use for lesions with complex characteristics15）.  They reported that the TLR 
rate was signicantly higher in the extended-use group compared to the standard-use group 
（standard : 2.8％ vs extended : 5.0％ ; P＜ 0.001）.
　A number of factors associated with a higher risk of TLR in ZES-treated patients have 
been reported in many studies.  For example, Mehta et al compared patients treated with 
ENDEAVOR I, II, or III who required TLR to patients who did not require TLR16）. 
Multivariate analysis suggested that older age （OR : 1.03 ; 95％ CI : 1.00-1.06）, male sex 
（OR : 1.79 ; 95％ CI : 0.88-3.65）, and longer lesion length （OR : 1.03 ; 95％ CI : 0.99-1.07） 
were independent risk factors for TLR after ZES implantation16）.  In our study, multivari-
ate analysis identied pre-MLD and dialysis as predictors of TLR in the ZES group.  It is 
well known that patients on dialysis have lesions with more complex characteristics, such as 
increased media thickness, massive calcication of coronary lesions, and multi-vessel disease, 
compared to patients not on dialysis.  To the best of our knowledge, no study has focused 
on dialysis in ZES-treated patients.  The reasons for this remain unclear.  Further studies 
will be necessary to conrm these results.
　Many studies have compared ZESs with other DESs 3, 4, 8）, but few studies have focused 
on differential lesion complexity.  Leon et al concluded that ZESs have similar levels 
of clinical safety and efcacy as PESs in simple and medium complexity single de novo 
lesions3）.  Similarly, Stefanini et al compared ZESs with EESs on the basis of lesion 
complexity and reported that the newer-generation ZESs and EESs proved to be safe and 
effective, regardless of complexity, with similar clinical and angiographic outcomes obtained 
for both stent types over one year8）.  However, the denitions of complexity used in these 
articles were slightly different from the denitions used in this report.  For example, in the 
latter article, the denition of “complex” included characteristics such as acute MI within 
72 h, left ventricular ejection fractions less than 30％, renal insufciency or failure, treat-
ment of bifurcations, saphenous vein grafts, arterial grafts, in-stent restenosis, unprotected left 
main lesions, treatment of more than two vessels, lesion lengths over 27 mm, more than 
one lesion / vessel, lesion with thrombus, or lesion with total occlusion8）.  As described in 
the Methods section, we dened A / B1 lesions as “simple” lesions and B2 / C lesions as 
“complex” lesions.  By isolating complex lesions from lesions with the clinical characteristics 
described by Stefanini et al8）, we were able to design this study such that the clinical out-
comes attributable to specic types of lesion complexity could be assessed.  Therefore, it is 
difcult to simply compare the results from other studies to our results.
　Although the decision to use ZESs should not be negatively inuenced by lesion com-
plexity, a greater late loss was found to be associated with a greater risk for TLR.  In addi-
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tion, both the mid-term outcomes and the long-term outcomes, such as late stent thrombosis 
and VLST, should be considered.  Recent studies using IVUS 17）, optical coherence tomog-
raphy 18）, and angioscopy19） reported that DESs demonstrated reduced late loss and had an 
inhibitory effect on neointimal hyperplasia but might be associated with a risk of late stent 
thrombosis or VLST due to incomplete neointimal coverage19）.  According to these articles, 
neointimal coverage after ZES implantation was nearly complete, which was similar to the 
pattern observed with BMSs when compared to the rst-generation DESs.  A pooled analy-
sis with a long-term follow-up of ZES-treated patients indicated that the frequency of VLST 
was less than 1％, which was similar to results observed after BMS treatment20）.  Kang et 
al compared ZESs with SESs, and PESs with IVUS and reported that ZESs had no late 
stent malpositions21）.  Although a larger amount of neointimal hyperplasia leads to the need 
for TLR, the coverage of ZES struts with neointimal hyperplasia may offer a protective 
advantage for early vessel healing.  Thus, the greater late loss of ZESs may not translate 
into worse clinical outcomes, and is therefore not necessarily a disadvantage of ZESs.  In 
addition, it is unknown whether there are differences in late safety outcomes specic to the 
different types of DESs relative to the duration of dual antiplatelet therapy （DAPT）.  It 
is believed that the duration of DAPT after ZES implantation may be shorter compared 
to other DESs due to the more rapid elution kinetics of zotarolimus from the phosphoryl-
choline polymer22）.  The overall attributes of ZESs versus other stents must be considered 
when making decisions in clinical practice.
Study limitations
　This study has several limitations that should be noted.  Firstly, this study was conducted 
at a single center, was retrospective, was relatively small, and patients were not randomly 
assigned to given DES types.  The unblended evaluation of stent type was at the discretion 
of the operators.  Secondly, we only analyzed the patients up to one year post-implantation 
and did not investigate long-term follow-ups.  A one-year follow-up may be too short to 
capture late events, such as VLST, after implantation of these DESs.  A longer follow-up is 
necessary to assess the safety and efcacy of ZES implantations.  Thirdly, the eight-month 
angiographic follow-up rate was relatively low （51％） compared to previous reports.
Conclusion
　Our study suggested that patients treated with ZESs demonstrated excellent mid-term 
angiographic and clinical outcomes for simple lesions compared to those treated with PESs, 
but it is necessary to implant ZESs carefully in complex lesions.  However, the decision to 
use ZESs should not be negatively inuenced by lesion complexity alone.  Both mid-term 
and long-term outcomes should be considered.  Therefore, the overall attributes of ZESs 
versus other DESs must be considered when making decisions in clinical practice.
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